Work in this area in ongoing; thus, once identified, clinically safe and effective AQP1 inhibitors may represent a novel class of antiplatelet drugs for the management of acute coronary syndrome, coronary artery disease, and stroke. The gene discussed is AQP1; the disease is acute coronary syndrome.